Transcranial direct current stimulation for the treatment of major depressive disorder: A summary of preclinical, clinical and translational findings

Andre Russowsky Brunoni, Roberta Ferrucci, Felipe Fregni, Paulo Sergio Boggio, Alberto Priori

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is a common psychiatric illness, with 6-12% lifetime prevalence. It is also among the five most disabling diseases worldwide. Current pharmacological treatments, although relatively effective, present important side effects that lead to treatment discontinuation. Therefore, novel treatment options for MDD are needed. Here, we discuss the recent advancements of one new neuromodulatory technique - transcranial direct current stimulation (tDCS) - that has undergone intensive research over the past decade with promising results. tDCS is based on the application of weak, direct electric current over the scalp, leading to cortical hypo- or hyper-polarization according to the specified parameters. Recent studies have shown that tDCS is able to induce potent changes in cortical excitability as well as to elicit long-lasting changes in brain activity. Moreover, tDCS is a technique with a low rate of reported side effects, relatively easy to apply and less expensive than other neuromodulatory techniques - appealing characteristics for clinical use. In the past years, 4 of 6 phase II clinical trials and one recent meta-analysis have shown positive results in ameliorating depression symptoms. tDCS has some interesting, unique aspects such as noninvasiveness and low rate of adverse effects, being a putative substitutive/augmentative agent for antidepressant drugs, and low-cost and portability, making it suitable for use in clinical practice. Still, further phase II and phase III trials are needed as to better clarify tDCS role in the therapeutic arsenal of MDD.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume39
Issue number1
DOIs
Publication statusPublished - Oct 1 2012

Fingerprint

Major Depressive Disorder
Therapeutics
Phase II Clinical Trials
Drug Costs
Scalp
Antidepressive Agents
Psychiatry
Meta-Analysis
Transcranial Direct Current Stimulation
Pharmacology
Depression
Brain
Research

Keywords

  • Clinical trial
  • Major depressive disorder
  • Non-invasive brain stimulation
  • Review
  • Transcranial direct current stimulation

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Transcranial direct current stimulation for the treatment of major depressive disorder : A summary of preclinical, clinical and translational findings. / Brunoni, Andre Russowsky; Ferrucci, Roberta; Fregni, Felipe; Boggio, Paulo Sergio; Priori, Alberto.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 39, No. 1, 01.10.2012, p. 9-16.

Research output: Contribution to journalArticle

@article{d1ece8d82c304726b9d4a9c7ba77775a,
title = "Transcranial direct current stimulation for the treatment of major depressive disorder: A summary of preclinical, clinical and translational findings",
abstract = "Major depressive disorder (MDD) is a common psychiatric illness, with 6-12{\%} lifetime prevalence. It is also among the five most disabling diseases worldwide. Current pharmacological treatments, although relatively effective, present important side effects that lead to treatment discontinuation. Therefore, novel treatment options for MDD are needed. Here, we discuss the recent advancements of one new neuromodulatory technique - transcranial direct current stimulation (tDCS) - that has undergone intensive research over the past decade with promising results. tDCS is based on the application of weak, direct electric current over the scalp, leading to cortical hypo- or hyper-polarization according to the specified parameters. Recent studies have shown that tDCS is able to induce potent changes in cortical excitability as well as to elicit long-lasting changes in brain activity. Moreover, tDCS is a technique with a low rate of reported side effects, relatively easy to apply and less expensive than other neuromodulatory techniques - appealing characteristics for clinical use. In the past years, 4 of 6 phase II clinical trials and one recent meta-analysis have shown positive results in ameliorating depression symptoms. tDCS has some interesting, unique aspects such as noninvasiveness and low rate of adverse effects, being a putative substitutive/augmentative agent for antidepressant drugs, and low-cost and portability, making it suitable for use in clinical practice. Still, further phase II and phase III trials are needed as to better clarify tDCS role in the therapeutic arsenal of MDD.",
keywords = "Clinical trial, Major depressive disorder, Non-invasive brain stimulation, Review, Transcranial direct current stimulation",
author = "Brunoni, {Andre Russowsky} and Roberta Ferrucci and Felipe Fregni and Boggio, {Paulo Sergio} and Alberto Priori",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.pnpbp.2012.05.016",
language = "English",
volume = "39",
pages = "9--16",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Transcranial direct current stimulation for the treatment of major depressive disorder

T2 - A summary of preclinical, clinical and translational findings

AU - Brunoni, Andre Russowsky

AU - Ferrucci, Roberta

AU - Fregni, Felipe

AU - Boggio, Paulo Sergio

AU - Priori, Alberto

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Major depressive disorder (MDD) is a common psychiatric illness, with 6-12% lifetime prevalence. It is also among the five most disabling diseases worldwide. Current pharmacological treatments, although relatively effective, present important side effects that lead to treatment discontinuation. Therefore, novel treatment options for MDD are needed. Here, we discuss the recent advancements of one new neuromodulatory technique - transcranial direct current stimulation (tDCS) - that has undergone intensive research over the past decade with promising results. tDCS is based on the application of weak, direct electric current over the scalp, leading to cortical hypo- or hyper-polarization according to the specified parameters. Recent studies have shown that tDCS is able to induce potent changes in cortical excitability as well as to elicit long-lasting changes in brain activity. Moreover, tDCS is a technique with a low rate of reported side effects, relatively easy to apply and less expensive than other neuromodulatory techniques - appealing characteristics for clinical use. In the past years, 4 of 6 phase II clinical trials and one recent meta-analysis have shown positive results in ameliorating depression symptoms. tDCS has some interesting, unique aspects such as noninvasiveness and low rate of adverse effects, being a putative substitutive/augmentative agent for antidepressant drugs, and low-cost and portability, making it suitable for use in clinical practice. Still, further phase II and phase III trials are needed as to better clarify tDCS role in the therapeutic arsenal of MDD.

AB - Major depressive disorder (MDD) is a common psychiatric illness, with 6-12% lifetime prevalence. It is also among the five most disabling diseases worldwide. Current pharmacological treatments, although relatively effective, present important side effects that lead to treatment discontinuation. Therefore, novel treatment options for MDD are needed. Here, we discuss the recent advancements of one new neuromodulatory technique - transcranial direct current stimulation (tDCS) - that has undergone intensive research over the past decade with promising results. tDCS is based on the application of weak, direct electric current over the scalp, leading to cortical hypo- or hyper-polarization according to the specified parameters. Recent studies have shown that tDCS is able to induce potent changes in cortical excitability as well as to elicit long-lasting changes in brain activity. Moreover, tDCS is a technique with a low rate of reported side effects, relatively easy to apply and less expensive than other neuromodulatory techniques - appealing characteristics for clinical use. In the past years, 4 of 6 phase II clinical trials and one recent meta-analysis have shown positive results in ameliorating depression symptoms. tDCS has some interesting, unique aspects such as noninvasiveness and low rate of adverse effects, being a putative substitutive/augmentative agent for antidepressant drugs, and low-cost and portability, making it suitable for use in clinical practice. Still, further phase II and phase III trials are needed as to better clarify tDCS role in the therapeutic arsenal of MDD.

KW - Clinical trial

KW - Major depressive disorder

KW - Non-invasive brain stimulation

KW - Review

KW - Transcranial direct current stimulation

UR - http://www.scopus.com/inward/record.url?scp=84864515633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864515633&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2012.05.016

DO - 10.1016/j.pnpbp.2012.05.016

M3 - Article

C2 - 22651961

AN - SCOPUS:84864515633

VL - 39

SP - 9

EP - 16

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -